Investigating Ras homolog gene family member C (RhoC) and Ki67 expression following external beam radiation therapy show increased RhoC expression in relapsing prostate cancer xenografts.

Autor: Kristiansson A; Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Oncology and pathology, Lund, Sweden; Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Section for Pediatrics, Lund, Sweden; Department of Neonatology, Skåne University Hospital, Lund, Sweden., Ceberg C; Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Medical Radiation Physics, Lund, Sweden., Bjartell A; Lund University, Faculty of Medicine, Department of Translational Medicine, Urological Cancers, Malmö, Sweden., Ceder J; Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Oncology and pathology, Lund, Sweden., Timmermand OV; Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Oncology and pathology, Lund, Sweden. Electronic address: oskar.vilhelmsson_timmermand@med.lu.se.
Jazyk: angličtina
Zdroj: Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2024 Oct 08; Vol. 728, pp. 150324. Date of Electronic Publication: 2024 Jun 28.
DOI: 10.1016/j.bbrc.2024.150324
Abstrakt: Ras homolog gene family member C (RhoC) is a GTPase involved in cell migration, implicated in epithelial-mesenchymal transition and treatment resistance and metastasis of cancer. For example, RhoC has been shown to be involved in resistance to radiation in cervical carcinoma. Here, the effect of X-ray irradiation on RhoC expression in prostate cancer (PCa) xenografts was investigated in both xenografts in regression and relapse. Male BALB/cAnNRj-Foxn1 nu/nu mice were inoculated with 4-6 million LNCaP-FGC cells and established xenografts were irradiated with X-rays (200 kV, 1 Gymin -1 ), 5, 10 or 15 Gy using a Gulmay Medical X-ray system. Expression of RhoC and Ki67, a known proliferation marker, was investigated in xenografts, given 15 Gy, 7 days (midst response as measured by size) or 3 weeks (relapse) post irradiation. Staining was quantified using the Halo software (v2.3.2089.34) with the Indica Labs - cytonuclear v1.6 algorithm. RhoC and Ki67 staining was divided into weak, medium, and strong staining and the percentage of cells stained, single and dual staining, was quantified. The HALO software was further used to classify the tissue in each section so that analysis of RhoC and Ki67 expression in cancer cells, stroma and necrotic areas could be done separately. The results showed that RhoC expression in cancer and stroma cells was significantly higher in relapsed xenografts than in those in regression. This was not seen for Ki67 staining, where the percentage of stained cells were the same in regressing and relapsing tumors. RhoC could be a useful biomarker to confirm relapse following external beam radiation therapy.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Oskar Vilhelmsson Timmerand reports financial support was provided by RhoVac Aps. Jens Ceder reports financial support was provided by RhoVac Aps. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: